{"groups":[{"description":"All patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase. Patients included patients with pancreatic neuroendocrine tumors (PNETs), pituitary NETs (PiNETs), Ectopic ACTH-secreting tumor (EAS) \\& Nelson's syndrome.","id":"FG000","title":"Pasireotide LAR 60mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Abnormal laboratory value(s)"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Abnormal test procedure result(s)"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Administrative problems"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"New cancer therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"22"}],"type":"Unsatisfactory therapeutic effect"},{"reasons":[{"groupId":"FG000","numSubjects":"27"}],"type":"Completed M6/did not enter extension"},{"reasons":[{"groupId":"FG000","numSubjects":"28"}],"type":"Discontinued prior to M*"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"118"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"90"}],"type":"Completed Month 6 (M6)"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"Entered in Extension"},{"achievements":[{"comment":"Completed = Completed extension","groupId":"FG000","numSubjects":"22"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"96"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"For all other individual indications, the numbers of patients in the efficacy analyzable sets were less than 6 and therefore no responder analyses were carried out for these indications."}